The China diabetes devices market size is anticipated to reach USD 3.18 billion by 2030 and is anticipated to grow at a CAGR of 9.11% from 2024 to 2030. The major factors contributing to market growth include the increasing prevalence of diabetes, attributed to lifestyle changes, urbanization, and an aging population. For instance, according to the International Federation of Diabetes, in 2021 there were about 140.86 million diabetes cases in China, which are further estimated to reach 164.06 million by 2030. This surge in diabetes cases has created a substantial demand for advanced diabetes management tools, including blood glucose monitoring devices, insulin delivery systems, and continuous glucose monitors (CGMs).
Technological advancements and innovation are further expanding market by addressing the diverse needs of its large population. Innovations in diabetes care devices, such as continuous glucose monitors (CGMs), smart insulin pens, and wearable insulin pumps, have made them more user-friendly, portable, and efficient. These devices now offer features like real-time glucose monitoring, smartphone connectivity, and data analytics, enabling patients to better manage their condition with minimal effort and greater accuracy. Moreover, advancements in sensor technology and artificial intelligence have led to more precise and non-invasive glucose monitoring solutions, which enhance patient comfort and compliance. The development of cost-effective devices tailored to the needs of the Chinese market, such as locally manufactured blood glucose meters and low-cost test strips, has made diabetes management more accessible to a broader segment of the population, including those in rural and underserved areas.
The market growth market is further significantly fueled by increasing awareness about diabetes and its management among both patients and healthcare professionals. Public health campaigns, educational programs, and community outreach efforts by the government and non-governmental organizations have played a crucial role in raising awareness about the importance of early diagnosis, regular monitoring, and effective management of diabetes. Furthermore, companies operating in the diabetes devices market are working to improve their product offerings by upgrading their products, leveraging important cooperative drives, as well as considering acquisitions and government approvals these efforts are aimed at expanding their customer base and gaining a larger share of the market.
This product will be delivered within 1-3 business days.
Technological advancements and innovation are further expanding market by addressing the diverse needs of its large population. Innovations in diabetes care devices, such as continuous glucose monitors (CGMs), smart insulin pens, and wearable insulin pumps, have made them more user-friendly, portable, and efficient. These devices now offer features like real-time glucose monitoring, smartphone connectivity, and data analytics, enabling patients to better manage their condition with minimal effort and greater accuracy. Moreover, advancements in sensor technology and artificial intelligence have led to more precise and non-invasive glucose monitoring solutions, which enhance patient comfort and compliance. The development of cost-effective devices tailored to the needs of the Chinese market, such as locally manufactured blood glucose meters and low-cost test strips, has made diabetes management more accessible to a broader segment of the population, including those in rural and underserved areas.
The market growth market is further significantly fueled by increasing awareness about diabetes and its management among both patients and healthcare professionals. Public health campaigns, educational programs, and community outreach efforts by the government and non-governmental organizations have played a crucial role in raising awareness about the importance of early diagnosis, regular monitoring, and effective management of diabetes. Furthermore, companies operating in the diabetes devices market are working to improve their product offerings by upgrading their products, leveraging important cooperative drives, as well as considering acquisitions and government approvals these efforts are aimed at expanding their customer base and gaining a larger share of the market.
China Diabetes Devices Market Report Highlights
- Based on type segment, the insulin delivery devices segment dominated the market with a share of 54.2% in 2023 and is further anticipated to grow at the fastest CAGR from 2024 to 2030 due to convenience and ease of use of insulin pens compared to traditional syringes
- Based on distribution channel, the hospital pharmacies segment held the largest revenue share of more than 50% in 2023 due to the important role of hospital pharmacies as primary access points for patients undergoing diabetes care in these healthcare facilities
- Retail pharmacies are expected to grow ta fastest CAGR from 2024 to 2030 owing to the accessibility and convenience offered by retail pharmacies to patients
- Based on end use, the hospitals segment held a majority share of the market of 40.8% in 2023, driven by the increasing patient preference for hospital settings and favorable government healthcare policies
- The diagnostic centers segment is expected to witness a significant CAGR of over 9.7% during the forecast period. This can be attributed to the increasing focus on early disease detection and prevention in the country’s population
The leading players in the China Diabetes Devices market include:
- Abbott
- F. Hoffmann-La Roche Ltd
- Medtronic
- Dexcom, Inc.
- BD
- Ascensia Diabetes Care Holdings AG
- Novo Nordisk A/S
- AstraZeneca
- Sanofi
- Sinocare
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Diabetes Devices Market Variables, Trends & Scope
Chapter 4. China Diabetes Devices Market: Type Estimates & Trend Analysis
Chapter 5. China Diabetes Devices Market: Distribution Channel Estimates & Trend Analysis
Chapter 6. China Diabetes Devices Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the China Diabetes Devices market include:- Abbott
- F. Hoffmann-La Roche Ltd
- Medtronic
- Dexcom, Inc.
- BD
- Ascensia Diabetes Care Holdings AG
- Novo Nordisk A/S
- AstraZeneca
- Sanofi
- Sinocare
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.73 Billion |
| Forecasted Market Value ( USD | $ 3.18 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | China |
| No. of Companies Mentioned | 11 |
